Tran Raymond, Hoesli Corinne A, Moraes Christopher
Department of Chemical Engineering, McGill University, Canada.
Integr Biol (Camb). 2016 Jul 11;8(7):737-40. doi: 10.1039/c6ib90021f.
Induced pluripotent stem cells (iPSCs) have opened new doors in providing an ethical, patient-specific cell source towards tissue engineering. Developing these therapies involves the production of reprogrammed iPSCs, expanding them while maintaining pluripotency, then differentiating them into functional tissues. To bring these therapies to the clinic, efficient and GMP-compliant manufacturing methods are required. In this Research Highlight, we describe recent innovations to several aspects of the pluripotent cell therapy pipeline.
诱导多能干细胞（iPSC）为组织工程提供了一种符合伦理、针对患者的细胞来源，从而打开了新的大门。开发这些疗法涉及重编程iPSC的生产，在维持多能性的同时进行扩增，然后将其分化为功能性组织。为了将这些疗法应用于临床，需要高效且符合药品生产质量管理规范（GMP）的制造方法。在本研究亮点中，我们描述了多能细胞治疗流程几个方面的最新创新。
